$CYCN
Cyclerion Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024054602 Filed on May 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $105.0K $44.00K
YoY Change -88.15% -98.83%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.384M $1.618M
YoY Change -67.38% -77.02%
Operating Profit -$1.384M -$1.618M
YoY Change -67.38% -77.02%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $62.00K $76.00K
YoY Change 0.0% -13.64%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.322M -$1.542M
YoY Change -68.38% -77.83%
Net Earnings / Revenue
Basic Earnings Per Share -$0.53 -$0.62
Diluted Earnings Per Share -$0.53 -$0.62
COMMON SHARES
Basic Shares Outstanding 2.710M 2.710M
Diluted Shares Outstanding 2.510M 2.494M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.588M $5.696M
YoY Change -18.67% -20.55%
Cash & Equivalents $4.588M $5.696M
Short-Term Investments
Other Short-Term Assets $11.00K $10.00K
YoY Change -99.25% -98.01%
Inventory
Prepaid Expenses $116.0K $308.0K
Receivables
Other Receivables
Total Short-Term Assets $4.715M $6.014M
YoY Change -33.71% -27.85%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.350M $5.350M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $5.350M $5.350M
YoY Change 79.29% 71.42%
TOTAL ASSETS
Total Short-Term Assets $4.715M $6.014M
Total Long-Term Assets $5.350M $5.350M
Total Assets $10.07M $11.36M
YoY Change -0.32% -0.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $651.0K $741.0K
YoY Change -65.08% -81.12%
Accrued Expenses $427.0K $539.0K
YoY Change -78.36% -84.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.282M $1.441M
YoY Change -74.09% -80.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.282M $1.441M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.282M $1.441M
YoY Change -74.09% -80.87%
SHAREHOLDERS EQUITY
Retained Earnings -$267.3M -$266.0M
YoY Change -1.11% -0.06%
Common Stock $276.1M $275.9M
YoY Change 0.23% 2.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.783M $9.923M
YoY Change
Total Liabilities & Shareholders Equity $10.07M $11.36M
YoY Change -0.32% -0.8%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$1.322M -$1.542M
YoY Change -68.38% -77.83%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.106M -$1.871M
YoY Change -83.13% -69.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.106M -1.871M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000
Net Change In Cash -1.106M -1.875M
YoY Change -27.76% -69.82%
FREE CASH FLOW
Cash From Operating Activities -$1.106M -$1.871M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001755237
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38787
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CYCLERION THERAPEUTICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1895370
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
245 First Street, 18th Floor
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2024Q1 dei City Area Code
CityAreaCode
857
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
327-8778
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, no par value
CY2024Q1 dei Trading Symbol
TradingSymbol
CYCN
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2710096
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5696000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7571000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
308000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
442000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
10000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
11000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
6014000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
8024000
CY2024Q1 us-gaap Other Long Term Investments
OtherLongTermInvestments
5350000
CY2023Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
5350000
CY2024Q1 us-gaap Assets
Assets
11364000
CY2023Q4 us-gaap Assets
Assets
13374000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
741000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1198000
CY2024Q1 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
90000
CY2023Q4 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
90000
CY2024Q1 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
610000
CY2023Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
798000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1441000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2086000
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2710096
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2645096
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2499601
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2474159
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
275898000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
275717000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-265959000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264417000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9923000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11288000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11364000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13374000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
572000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1574000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2703000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
1618000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
3275000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1618000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3275000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
76000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
88000
CY2024Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-1542000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3187000
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-3767000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1542000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6954000
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.62
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.62
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.46
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.46
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.73
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.73
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.2
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.2
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2494000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2494000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2176000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2176000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1542000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6954000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-1546000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6953000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10452000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6954000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
426000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3925000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11288000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1542000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
181000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9923000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-1542000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-6954000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
181000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
426000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-134000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-238000
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
0
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-34000
CY2024Q1 cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
0
CY2023Q1 cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-47000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-91000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-456000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
955000
CY2024Q1 cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
0
CY2023Q1 cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-670000
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-188000
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-381000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1871000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6214000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1875000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6213000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7571000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13382000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5696000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7169000
CY2023Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
8000000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2400000
CY2019Q2 dei Entity Number Of Employees
EntityNumberOfEmployees
0
CY2019Q4 dei Entity Number Of Employees
EntityNumberOfEmployees
0
CY2023Q1 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
5000000
CY2020Q3 cycn Cash Commission Percentage Of Gross Proceeds Of Sales Of Common Stock
CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock
0.03
cycn Common Stock Issued Or Sold Under The Atm Offering
CommonStockIssuedOrSoldUnderTheAtmOffering
3353059000
cycn Common Stock Issued Or Sold Under The Atm Offering
CommonStockIssuedOrSoldUnderTheAtmOffering
0
CY2023Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
8000000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2400000
CY2024Q1 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
126000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
126000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
126000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
126000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2024Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
22000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
11000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
427000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
685000
CY2024Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
161000
CY2023Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
102000
CY2024Q1 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
610000
CY2023Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
798000
CY2024Q1 us-gaap Severance Costs1
SeveranceCosts1
100000
CY2020Q3 cycn Rentable Square Feet Terminated From Lease Agreement
RentableSquareFeetTerminatedFromLeaseAgreement
15700
CY2024Q1 cycn Sublease Termination Agreement Estimated Fair Value Of Rooms
SubleaseTerminationAgreementEstimatedFairValueOfRooms
1500000
CY2024Q1 cycn Sublease Termination Agreement Estimated Fair Value Of Services
SubleaseTerminationAgreementEstimatedFairValueOfServices
2900000
CY2024Q1 cycn Prepaid Rooms Balance Related To Other Assets
PrepaidRoomsBalanceRelatedToOtherAssets
1400000
CY2024Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P8Y10M17D
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2024Q1 cycn Services Expense
ServicesExpense
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
181000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
426000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7500
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
40.2
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y2M19D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-1542000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3187000
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-3767000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1542000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6954000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2494000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2494000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2176000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2176000
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.62
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.62
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.46
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.46
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.73
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.73
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.2
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.2
CY2024Q1 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
853067000
CY2023Q1 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
421374000
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
809000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
668000
CY2023Q1 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
CY2023Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
141000

Files In Submission

Name View Source Status
0000950170-24-054602-index-headers.html Edgar Link pending
0000950170-24-054602-index.html Edgar Link pending
0000950170-24-054602.txt Edgar Link pending
0000950170-24-054602-xbrl.zip Edgar Link pending
cycn-20240331.htm Edgar Link pending
cycn-20240331.xsd Edgar Link pending
cycn-ex31_1.htm Edgar Link pending
cycn-ex31_2.htm Edgar Link pending
cycn-ex32_1.htm Edgar Link pending
cycn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cycn-20240331_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending